Drug or treatment

Disitamab clinical trials

• 32Clinical trials
• 13Countries

Newest trials

All recruiting trials (32)

• Disitamab Vedotin Plus Radiotherapy for HER2-Expressing Upper Tract Urothelial Carcinoma After Surgery

  This study tests whether disitamab vedotin with radiotherapy can improve outcomes for people with HER2-expressing upper tract urothelial carcinoma after radical surgery who can’t receive cisplatin.

  Recruiting Phase 3 Peking University First Hospital · Beijing · NCT07498907

• Disitamab vedotin plus SOX versus SOX alone as adjuvant treatment for HER2-moderate/high stage III gastric cancer after surgery

  This trial will test whether adding disitamab vedotin to standard SOX chemotherapy helps people with HER2-moderate/high stage III gastric cancer after surgery stay cancer-free longer or live longer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07474324

• Disitamab vedotin plus bevacizumab for HER2-low metastatic breast cancer after T‑DxD failure

  This study will try disitamab vedotin combined with bevacizumab in adults with HER2‑low metastatic breast cancer whose disease progressed after trastuzumab deruxtecan.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07446452

• Disitamab vedotin plus trastuzumab and tislelizumab versus chemotherapy plus trastuzumab (± pembrolizumab) for HER2‑high advanced gastric or gastroesophageal junction adenocarcinoma

  This trial tests whether combining disitamab vedotin with trastuzumab and the immunotherapy tislelizumab works better than standard chemotherapy with trastuzumab (with or without pembrolizumab) as first‑line treatment for people with HER2‑high advanced gastric or gastroesophageal junction cancer.

  Recruiting Phase 3 RemeGen Co., Ltd. · Beijing, BJ-Beijing · NCT07315750

• Disitamab vedotin plus carboplatin and bevacizumab as first-line and maintenance treatment for HER2-expressing, HRD-negative high-risk ovarian cancer

  This study tests whether adding disitamab vedotin to carboplatin and bevacizumab helps people with HER2-expressing, HRD-negative high-risk ovarian cancer as first-line and maintenance treatment.

  Recruiting Phase 2 Jiangsu Cancer Institute & Hospital · Nanjing, Jiangsu and 1 other locations · NCT07311577

• Disitamab Vedotin plus BCG vs BCG alone in HER2-expressing high-risk NMIBC

  This study tests whether adding disitamab vedotin to BCG helps people with early, high-risk bladder cancer that hasn’t spread outside the bladder.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07207824

• Conversion therapy using disitamab vedotin (RC48), sintilimab, and SOX for HER2 IHC 1+ or 2+ unresectable gastric cancer

  This trial will test whether combining disitamab vedotin (RC48), the immunotherapy sintilimab, and SOX chemotherapy can shrink tumors enough to allow surgery in people with initially unresectable HER2 IHC 1+ or 2+ gastric cancer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07194005

• Disitamab Vedotin plus bicalutamide for HER2/AR-positive scrotal Paget disease

  This trial will test whether combining Disitamab Vedotin and bicalutamide helps adults with advanced HER2-positive, AR-positive extramammary Paget disease of the scrotum.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07117851

• Disitamab vedotin plus abiraterone for HER2-expressing metastatic castration-resistant prostate cancer

  This trial tests whether adding the antibody–drug conjugate disitamab vedotin to abiraterone helps men with HER2-expressing metastatic castration-resistant prostate cancer.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07093866

• RC48 with bevacizumab or pyrotinib for HER2-positive metastatic breast cancer after T-Dxd failure

  This trial will try RC48 together with either bevacizumab or pyrotinib in adults with HER2-positive metastatic breast cancer whose disease has progressed after trastuzumab deruxtecan (T-Dxd).

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07065435

• Treatment for advanced extramammary Paget disease of the scrotum

  This study is testing a new combination of two drugs to see if they can help people with advanced HER2-positive extramammary Paget disease of the scrotum feel better and reduce their tumor size.

  Recruiting Phase 2 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06791070

• Combination treatment for resectable HER2-mutant non-small cell lung cancer

  This study is testing a new combination treatment for people with resectable HER2-mutant non-small cell lung cancer to see if it can improve their chances of recovery after surgery.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou · NCT06734182

• Combination treatment for advanced HER2-positive gastric cancer

  This study is testing a new combination of treatments for people with advanced HER2-positive gastric cancer to see if it works better than the standard chemotherapy options.

  Recruiting at 16 sites Phase 2 Qilu Hospital of Shandong University · Zhengzhou, Henan and 19 other locations · NCT06730373

• Combining Disitamab Vedotin with RC148 for treating HR-negative, HER2-low breast cancer

  This study is testing if a new combination of two treatments can help people with hard-to-treat HR-negative, HER2-low breast cancer feel better compared to standard options.

  Recruiting Phase 2 RemeGen Co., Ltd. · Beijing, Beijing Municipality · NCT06642545

• Combination therapy of Disitamab Vedotin and Trastuzumab for HER2 positive gastric cancer

  This study is testing a new combination of two drugs, Disitamab Vedotin and Trastuzumab, to see if it can help people with advanced HER2 positive gastric cancer who haven't responded to other treatments.

  Recruiting Phase 1/2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06572319

• Combination treatment for advanced gastric cancer with HER2 overexpression

  This study is testing a new combination treatment for patients with advanced gastric cancer that has high levels of HER2 to see if it can improve their outcomes.

  Recruiting at 2 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality and 1 other locations · NCT06560528

• Combining Disitamab Vedotin with Cisplatin for Cervical Cancer Treatment

  This study is testing if a new combination of Disitamab Vedotin and cisplatin can help patients with advanced cervical cancer feel better and improve their chances of successful surgery.

  Recruiting Qilu Hospital of Shandong University · Jinan, Shandong · NCT06558682

• Disitamab vedotin (RC48) with AK104 and bevacizumab for recurrent or persistent clear cell ovarian cancer

  This trial tests whether combining a HER2-targeted antibody–drug conjugate (disitamab vedotin) with the PD-1/CTLA-4 bispecific AK104 and bevacizumab helps people with recurrent or persistent ovarian clear cell carcinoma.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guanzhou, Guangdong · NCT06540729

• Neoadjuvant therapy for HER2 positive locally advanced gastric cancer

  This study is testing a new treatment plan that combines radiation and medications to see if it can help people with advanced stomach cancer get ready for surgery.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT06487429

• Evaluating a new treatment for HR-positive, HER2-low breast cancer

  This study is testing a new treatment combining Disitamab Vedotin and Toripalimab with chemotherapy to see if it helps people with HR-positive, HER2-low breast cancer before surgery.

  Recruiting Phase 2 RemeGen Co., Ltd. · Shanghai, Fudan University Shanghai Cancer Center · NCT06389006

• Evaluating a new treatment for high-risk bladder cancer that expresses HER2

  This study is testing a new treatment for high-risk bladder cancer that shows a specific protein called HER2 to see if it is safe and effective for patients.

  Recruiting at 2 sites Phase 1/2 RemeGen Co., Ltd. · Guangzhou, Guangdong and 5 other locations · NCT06378242

• Comparing disitamab vedotin and pyrotinib to standard treatment for HER2-positive advanced breast cancer

  This study is testing a new combination of disitamab vedotin and pyrotinib to see if it works better than the standard treatment for people with newly diagnosed HER2-positive advanced breast cancer.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06278870

• Neoadjuvant treatment for HR-negative, HER2 low-expressing breast cancer

  This study is testing a new combination treatment for people with HR-negative, HER2 low-expressing breast cancer to see if it helps them respond better than standard chemotherapy.

  Recruiting Phase 2 RemeGen Co., Ltd. · Changsha, Hunan and 4 other locations · NCT06227117

• Combining Disitamab Vedotin and Cadonilimab for HER2-expressing Gastric Cancer

  This study is testing if combining two treatments, Disitamab Vedotin and Cadonilimab, can help people with advanced gastric cancer that has not responded to earlier treatments.

  Recruiting at 5 sites Phase 2/3 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 11 other locations · NCT06221748

• Combination therapy for HER2-positive breast cancer

  This study tests a new combination of treatments for people with HER2-positive breast cancer to see if it helps them respond better before surgery.

  Recruiting Phase 2 RemeGen Co., Ltd. · Shanghai, Shanghai Municipality · NCT06178159

• Combination therapy for advanced gastric cancer

  This study is testing a new combination treatment for advanced gastric cancer to see if it works better than the usual options for patients with a specific type of the disease.

  Recruiting Phase 2 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 10 other locations · NCT06155383

• Combining Disitamab Vedotin with Radiotherapy for HER2 Positive Solid Tumors

  This study is testing if a new drug combined with radiation can help people with certain hard-to-treat tumors that have HER2 and who can't or don't want to use standard chemotherapy.

  Recruiting Phase 1 RemeGen Co., Ltd. · Jinan, Shandong · NCT05940896

• Disitamab Vedotin for treating hormone receptor positive, HER2-low metastatic breast cancer

  This study is testing a new drug called Disitamab Vedotin to see if it can help people with hormone receptor positive, HER2-low metastatic breast cancer who haven't responded to standard treatments.

  Recruiting at 3 sites Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 2 other locations · NCT05904964

• Evaluating Disitamab vedotin for breast cancer treatment

  This study is testing how well Disitamab vedotin works and how safe it is for people with breast cancer who have used or are using this treatment.

  Recruiting RenJi Hospital · Shanghai · NCT05851677

• Using Tislelizumab and Disitamab-vedotin for Neoadjuvant Therapy in High-risk Upper Tract Urothelial Carcinoma

  This study is testing a new combination of two drugs, tislelizumab and disitamab-vedotin, to see if they can safely help people with high-risk upper tract urothelial carcinoma before surgery, especially for those who can't take traditional chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin · NCT05837806

• Treatment for HER2-low advanced breast cancer using Disitamab vedotin

  This study is testing a new treatment called Disitamab vedotin for people with HER2-low advanced breast cancer who have already tried one round of chemotherapy to see if it can help them feel better and live longer.

  Recruiting RenJi Hospital · Shanghai · NCT05831878

• Treatment of HER2 expressing urothelial cancer with disitamab vedotin and pembrolizumab

  This study is testing if a new drug called disitamab vedotin, alone or with another drug called pembrolizumab, can help shrink tumors in patients with a specific type of bladder cancer that can't be surgically removed.

  Recruiting at 169 sites Phase 2 Seagen Inc. · Gilbert, Arizona and 220 other locations · NCT04879329

Quick answers

How many clinical trials of Disitamab are recruiting right now?

32, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 13 countries. The most sites are in China (31 trials), Argentina (1 trial), Australia (1 trial), Belgium (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 20, Phase 3: 5, Phase 1/2: 2, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →